- |||||||||| Journal: Superficial Soft-Tissue Sarcomas Rarely Require Advanced Soft-Tissue Reconstruction following Resection. (Pubmed Central) - Dec 24, 2017
Although concern about the morbidity associated with a free tissue transfer (ie, advanced reconstructive procedure) may potentially limit the adequacy of resection in some patients with S-STS, the results of this study showed that the majority of patients had complete excisions with negative margins and primary closure. Obtaining a negative margin when excising a known or suspected S-STS rarely requires an advanced reconstructive procedure and almost never results in loss of limb.
- |||||||||| dociparstat sodium (CX-01) / Cantex Pharma, Chimerix
Trial termination, Trial primary completion date: ODSH + ICE Chemotherapy in Pediatric Solid Tumors (clinicaltrials.gov) - Dec 22, 2017 P1, N=4, Terminated, The observed median PFS and overall survival in this large, international study can serve as a benchmark for future studies of doxorubicin in metastatic soft tissue sarcoma. Recruiting --> Terminated | Trial primary completion date: Dec 2016 --> Dec 2017; low accrual
- |||||||||| Review, Journal: Cancer of the Peripheral Nerve in Neurofibromatosis Type 1. (Pubmed Central) - Dec 21, 2017
In this review, we discuss the current state-of-the-art treatments for MPNSTs, latest therapeutic developments, and critical aspects of the underlying molecular and pathophysiology that appear promising for therapeutic developments in the future. In particular, we discuss the specific elements of cancer in the peripheral nerve and how that may impel development of unique therapies for this form of sarcoma.
- |||||||||| RRx-001 / EpicentRx
Biomarker, Preclinical, Journal: Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. (Pubmed Central) - Dec 20, 2017 The T150 min of CHP-100 tumors recovered to baseline by 24 h post-drug, suggesting a robust anti-oxidant response to the RRx-001 challenge that was presaged by a marked increase in perfusion at 1 h post-drug measured by DCE-MRI. MRI enhanced with Gd-LC7-SH provides a mechanistically rational biomarker of RRx-001 pharmacodynamics.
- |||||||||| alisertib (MLN8237) / Puma
Trial completion, Trial primary completion date, Metastases: Alisertib in Treating Patients With Advanced or Metastatic Sarcoma (clinicaltrials.gov) - Dec 19, 2017 P2, N=72, Completed, Active, not recruiting --> Completed | Trial primary completion date: May 2016 --> Jan 2015 Suspended --> Completed | Trial primary completion date: Feb 2016 --> Aug 2015
- |||||||||| Lartruvo (olaratumab) / Eli Lilly
Trial primary completion date, Combination therapy, Monotherapy: A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma (clinicaltrials.gov) - Dec 19, 2017 P1b, N=40, Recruiting, Recruiting --> Completed | N=30 --> 22 | Trial primary completion date: Dec 2015 --> Nov 2017 | Recruiting --> Completed | N=30 --> 22 | Trial primary completion date: Dec 2015 --> Nov 2017 | Recruiting --> Completed | N=30 --> 22 | Trial primary completion date: Dec 2015 --> Nov 2017 Trial primary completion date: Jul 2018 --> Mar 2018
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Clinical Trial,Phase I, Clinical Trial,Phase II, Journal: Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. (Pubmed Central) - Dec 17, 2017 P2 However, pembrolizumab showed encouraging activity in patients with undifferentiated pleomorphic sarcoma or dedifferentiated liposarcoma. Enrolment to expanded cohorts of those subtypes is ongoing to confirm and characterise the activity of pembrolizumab.
- |||||||||| Journal: Comprehensive Analysis of Hypermutation in Human Cancer. (Pubmed Central) - Dec 17, 2017
The order of mutational signatures identified previous treatment and germline replication repair deficiency, which improved management of patients and families. These data will inform tumor classification, genetic testing, and clinical trial design.
- |||||||||| Truseltiq (infigratinib) / BridgeBio, Pfizer, Xediton Pharma
Trial primary completion date, Combination therapy, Stroma, Metastases: BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) (clinicaltrials.gov) - Dec 15, 2017 P1/2, N=62, Active, not recruiting, ω-3 supplementation decreased Il-6 concentrations among HIV and HHV-8 co-infected Ugandans, which may have clinical benefit for KS patients. Trial primary completion date: Oct 2017 --> Oct 2018
- |||||||||| Journal: Primary Undifferentiated Pleomorphic Sarcoma of the Penis. (Pubmed Central) - Dec 14, 2017
The tumor was surgically excised, but the patient experienced local recurrence and, despite receiving chemotherapy and surgery, died of metastatic disease 15 months after initial presentation. Vigilance regarding biopsy and intervention for penile nodules may lead to early diagnosis and improved clinical outcomes.
- |||||||||| cytarabine / Generic mfg.
Review, Journal: Extramedullary acute myelogenous leukemia. (Pubmed Central) - Dec 13, 2017 Cytarabine-based remission induction regimens have been the most commonly used in the upfront setting...In this manuscript, we will review the recent literature about EM AML, focusing on therapy and proposing a treatment algorithm for managing this rare form of leukemia. Further studies addressing risk stratification, role of molecular and genetic aberrations, and optimal treatment strategies are warranted.
- |||||||||| Tevimbra (tislelizumab-jsgr) / BeiGene
Enrollment closed, Trial primary completion date, Metastases: BGB-A317_Study_001: Study of the Safety, Pharmacokinetics and Antitumor Activities of BGB-A317 in Participants With Advanced Tumors (clinicaltrials.gov) - Dec 13, 2017 P1a/1b, N=451, Active, not recruiting, Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2017 --> Apr 2018
- |||||||||| Journal: Pencil Beam Scanning Proton Therapy for Rhabdomyosarcoma of the Biliary Tract. (Pubmed Central) - Dec 13, 2017
Motion management and anatomical variations, such as intestinal filling or weight loss, requiring routine dosimetric evaluation and possible adaptive treatment planning, present challenges for the use of proton therapy. By taking advantage of the superior dose distribution of proton radiation, assessing the impact of tumor and anatomy motion, and performing regular dose evaluations, biliary tract RMS is an ideal diagnosis for pencil beam scanning proton therapy.
|